All In Biotech

Drug Trial Radar · NCT02159066

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.

Last checked: Nov 20, 2026Latest source record: Mar 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

158

Actual

Start

Jul 23, 2014

Primary completion

Jan 10, 2023

Study completion Jan 10, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 9, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Conditions

  • Melanoma

Interventions

  • LGX818Drug

    Combination of LGX818 and MEK162 (Part I)

  • MEK162Drug

    Combination of LGX818 and MEK162 (Part I)

  • LEE011Drug

    Combination of LGX818 + MEK162 + LEE011 (Part II)

  • BGJ398Drug

    Combination of LGX818 + MEK162 + BGJ398 (Part II)

  • BKM120Drug

    Combination of LGX818 + MEK162 + BKM120 (Part II)

  • INC280Drug

    Combination of LGX818 + MEK162 + INC280 (Part II)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR): Part IITime frame: From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (maximum treatment exposure for Part II was 97.0 weeks)

Locations

32 sites in 9 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California

  • Cancer Care Center

    Los Angeles, California

  • Doris Stein Research Center Building

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services

    Los Angeles, California

  • UCLA Dermatology Clinic

    Los Angeles, California

  • UCLA Oncology Center

    Los Angeles, California

  • UCLA Radiology

    Los Angeles, California

  • Memorial Sloan Kettering Cancer Center Attn: Geny O'neill

    New York, New York

  • Memorial Sloan Kettering Cancer Center Inpatient Hospital & Main Campus

    New York, New York

  • Memorial Sloan Kettering Cancer Center- Outpatient Clinic

    New York, New York

  • OHSU Knight Cancer Institute

    Portland, Oregon

  • OHSU Center for Health and Healing 2

    Portland, Oregon

  • OHSU Center for Health and Healing

    Portland, Oregon

  • OHSU Research Pharmacy Services

    Portland, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • East St Kilda Eye Clinic

    Melbourne, Victoria, Australia

  • Princess Margaret Cancer Center

    Toronto, Ontario, Canada

  • Sir Mortimer B. Davis-Jewish General Hospital

    Monteral, Quebec, Canada

  • Uniklinik Köln

    Cologne, Germany

  • Städtisches Klinikum München

    München, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • University Clinic Heidelberg PPDS

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany

  • U.O.C. Oncologia Medica e Terapie Innovative Dipartimento di Melanoma IRCCS Fondazione G. Pascale

    Naples, Italy

  • Azienda Ospedaliera Monaldi

    Naples, Campania, Italy

  • Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis

    Amsterdam, Netherlands

  • Hospital Universitario Vall d'Hebrón - PPDS

    Barcelona Cataluna, Barcelona, Spain

  • Universitätsspital Zürich

    Zurich Flughafen, Switzerland

  • Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.